entertainment -WSS

entertainment

author：entertainment 2025-08-12 09:12:53 - browse：17

President Joe Biden speaks and gestures at a podium outdoor — In addition to medical devices, the United States will raise tariffs on $18 billion worth of products including electric vehicles, batteries, and semiconductors. MANDEL NGAN/AFP via Getty Images

WASHINGTON — The Biden administration announced Tuesday that it’s raising taxes on a range of imported products from China, including syringes, needles, and surgical gloves.

Pitched as a plan to support American workers, the tariffs are meant to protect domestic manufacturers from China’s “unfair trade practices” and “artificially low-priced exports.” In addition to medical devices, the United States will raise tariffs on $18 billion worth of products including electric vehicles, batteries, and semiconductors.

Related: Drug supplies for millions would be jeopardized by U.S. crackdown on China biopharma industry, trade group says

The inclusion of syringes comes after the Food and Drug Administration’s repeated warnings to U.S. medical providers about quality issues with plastic syringes from China. The agency first alerted consumers in November 2023 about leaks and breaks associated with Chinese syringes. In March, the FDA called attention to three warning letters it sent to firms in China for selling syringes that had not received FDA clearance. It has since sent a warning letter to Cardinal Health.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease

WSS

AstraZeneca loses challenge to Medicare drug price negotiation

A daunting task: navigating dual Medicare, Medicaid eligibility

RaDonda Vaught to speak at CommonSpirit event on patient safety

A daunting task: navigating dual Medicare, Medicaid eligibility

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

FDA's Woodcock to retire early next year

entertainment

entertainment

Related: Drug supplies for millions would be jeopardized by U.S. crackdown on China biopharma industry, trade group says

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Jerome Adams on the need for new antivirals for Covid

Does good food count as health care? Study aims to find out

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Psychedelics group wrestles with new pharma identity

CRISPR pioneers react to Casgevy, first gene

Apple is now the first public company to be valued at $3 trillion

Covid isolation guidance eased by the CDC

Duchenne breakthrough therapy leaves behind pioneering families

Biotech companies concerned about China biosecurity crackdown

entertainment

Medical device lobby: We're tired of waiting on Medicare coverage

CRISPR pioneers react to Casgevy, first gene

FogPharma raises $145 million in rare Series E round

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Scientists unlock the key to scar

AstraZeneca loses challenge to Medicare drug price negotiation

leisure time

hotspot

hotspot

explore